BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 45 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2019. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $54,000 | -96.7% | 11,975 | -87.7% | 0.00% | -92.6% |
Q3 2020 | $1,649,000 | +24.2% | 97,455 | -17.8% | 0.05% | +58.8% |
Q2 2020 | $1,328,000 | +272.0% | 118,487 | +53.9% | 0.03% | +277.8% |
Q1 2020 | $357,000 | +32.2% | 76,967 | +21.9% | 0.01% | +125.0% |
Q4 2019 | $270,000 | -7.8% | 63,128 | -15.9% | 0.00% | +33.3% |
Q3 2019 | $293,000 | – | 75,071 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
Ergoteles LLC | 124,329 | $472,000 | 0.01% |
CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |